Companies ›Healthcare ›6999.TWO

6999.TWO — TPEx Medical Equipment, Supplies & Distribution

Han Biomedical Inc

$29,70

Open in Charts → Attach watcher ⌖

— —

TWD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

653,8M TWD

P/E

30,3x

EV / Rev

—

Div yield

1,65 %

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Han Biomedical Inc is a company in the Healthcare Services & Equipment sector, primarily engaged in the development and distribution of medical equipment and supplies.

Business. Han Biomedical Inc (6999.TWO) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, including capital equipment and consumables. It is listed on the Taiwan Premium Board (TPEx). Specific details regarding operating segments and geographic presence are not available.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryMedical Equipment, Supplies & Distribution

ActivityHealthcare Services & Equipment

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation→

30,3x

P/E

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 6999.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 6999.TWO. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Han Biomedical Inc (6999.TWO) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, including capital equipment and consumables. It is listed on the Taiwan Premium Board (TPEx). Specific details regarding operating segments and geographic presence are not available.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryMedical Equipment, Supplies & Distribution

ActivityHealthcare Services & Equipment

AI synthesis

GENERATED

Han Biomedical Inc has a market capitalization of TWD 683,565,750, with a market price of TWD 31.05 per share. The company has 22,015,000 basic and diluted shares outstanding, indicating no immediate dilution pressure from share issuance.

Profitability and return metrics are not available in the current dataset, as the valuation snapshot does not include ROIC, EBITDA margins, or other key performance indicators. Without these metrics, it is not possible to compare Han Biomedical Inc's performance to the cohort median or industry benchmarks.

The company's revenue concentration and geographic exposure are not disclosed in the available data. As a result, it is not possible to assess the risk associated with geographic or segment-level revenue concentration.

Growth trajectory is also not quantifiable at this time, as the outlook for the current and next fiscal year does not include numeric deltas or revenue growth projections. The absence of historical revenue data further limits the ability to assess growth trends.

Risk assessment indicates that liquidity risk could not be evaluated due to the lack of balance-sheet inputs and no going-concern language in the source documents. The company is currently assessed as having low dilution risk, with no immediate pressure from share issuance or capital-raising activities.

Recent events, including filings or transcripts, are not available in the current dataset. As a result, it is not possible to assess the impact of recent corporate actions or strategic developments on the company's financial position.

Key takeaways

Han Biomedical Inc has a market capitalization of TWD 683,565,750, with no immediate dilution pressure from share issuance.
Profitability and return metrics are not available, limiting the ability to assess performance relative to industry benchmarks.
Revenue concentration and geographic exposure are not disclosed, making it difficult to evaluate risk from segment or regional dependencies.
Growth trajectory and historical revenue data are not available, preventing a comprehensive assessment of the company's growth potential.
Liquidity risk could not be assessed due to the lack of balance-sheet inputs and no going-concern language in the source documents.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation FY

Market price

$29,70

Market cap

$683.6M

Enterprise valueⓘ

—

P/Eⓘ

30.3x

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted

Source documents

Han Biomedical Inc Market data — financials · 2026-05-27

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

6999.TWOCanonical

TPEx · TWD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskUnknown

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread